Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting.

IF 2.2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Clinical Trials Pub Date : 2024-10-12 DOI:10.1177/17407745241284786
Lingyun Ji, Todd A Alonzo
{"title":"Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting.","authors":"Lingyun Ji, Todd A Alonzo","doi":"10.1177/17407745241284786","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>For cancers with low incidence, low event rates, and a time-to-event endpoint, a randomized non-inferiority trial designed based on the logrank test can require a large sample size with significantly prolonged enrollment duration, making such a non-inferiority trial not feasible. This article evaluates a design based on a non-inferiority test of proportions, compares its required sample size to the non-inferiority logrank test, assesses whether there are scenarios for which a non-inferiority test of proportions can be more efficient, and provides guidelines in usage of a non-inferiority test of proportions.</p><p><strong>Methods: </strong>This article describes the sample size calculation for a randomized non-inferiority trial based on a non-inferiority logrank test or a non-inferiority test of proportions. The sample size required by the two design methods are compared for a wide range of scenarios, varying the underlying Weibull survival functions, the non-inferiority margin, and loss to follow-up rate.</p><p><strong>Results: </strong>Our results showed that there are scenarios for which the non-inferiority test of proportions can have significantly reduced sample size. Specifically, the non-inferiority test of proportions can be considered for cancers with more than 80% long-term survival rate. We provide guidance in choice of this design approach based on parameters of the Weibull survival functions, the non-inferiority margin, and loss to follow-up rate.</p><p><strong>Conclusion: </strong>For cancers with low incidence and low event rates, a non-inferiority trial based on the logrank test is not feasible due to its large required sample size and prolonged enrollment duration. The use of a non-inferiority test of proportions can make a randomized non-inferiority Phase III trial feasible.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745241284786"},"PeriodicalIF":2.2000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17407745241284786","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background/aims: For cancers with low incidence, low event rates, and a time-to-event endpoint, a randomized non-inferiority trial designed based on the logrank test can require a large sample size with significantly prolonged enrollment duration, making such a non-inferiority trial not feasible. This article evaluates a design based on a non-inferiority test of proportions, compares its required sample size to the non-inferiority logrank test, assesses whether there are scenarios for which a non-inferiority test of proportions can be more efficient, and provides guidelines in usage of a non-inferiority test of proportions.

Methods: This article describes the sample size calculation for a randomized non-inferiority trial based on a non-inferiority logrank test or a non-inferiority test of proportions. The sample size required by the two design methods are compared for a wide range of scenarios, varying the underlying Weibull survival functions, the non-inferiority margin, and loss to follow-up rate.

Results: Our results showed that there are scenarios for which the non-inferiority test of proportions can have significantly reduced sample size. Specifically, the non-inferiority test of proportions can be considered for cancers with more than 80% long-term survival rate. We provide guidance in choice of this design approach based on parameters of the Weibull survival functions, the non-inferiority margin, and loss to follow-up rate.

Conclusion: For cancers with low incidence and low event rates, a non-inferiority trial based on the logrank test is not feasible due to its large required sample size and prolonged enrollment duration. The use of a non-inferiority test of proportions can make a randomized non-inferiority Phase III trial feasible.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在设计以时间为终点的随机非劣效性试验时使用比例非劣效性检验,重点关注低事件率环境。
背景/目的:对于发病率低、事件发生率低且以时间为终点的癌症,基于logrank检验设计的随机非劣效性试验可能需要较大的样本量,且入组时间明显延长,因此这种非劣效性试验并不可行。本文评估了基于非劣效性比例检验的设计,比较了其与非劣效性 logrank 检验所需的样本量,评估了是否存在非劣效性比例检验更有效的情况,并提供了使用非劣效性比例检验的指南:本文介绍了基于非劣效 logrank 检验或非劣效比例检验的随机非劣效试验的样本量计算。文章比较了两种设计方法在不同情况下所需的样本量,包括基础 Weibull 生存函数、非劣效边际和随访损失率:结果:我们的研究结果表明,在某些情况下,比例非劣效性检验可以显著减少样本量。具体来说,对于长期生存率超过 80% 的癌症,可以考虑采用比例非劣效性检验。我们根据 Weibull 生存函数的参数、非劣效边际和随访损失率,为选择这种设计方法提供指导:结论:对于低发病率和低事件发生率的癌症,基于对数秩检验的非劣效性试验是不可行的,因为它所需的样本量大,入组时间长。使用比例非劣效性检验可以使随机非劣效性 III 期试验变得可行。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Trials
Clinical Trials 医学-医学:研究与实验
CiteScore
4.10
自引率
3.70%
发文量
82
审稿时长
6-12 weeks
期刊介绍: Clinical Trials is dedicated to advancing knowledge on the design and conduct of clinical trials related research methodologies. Covering the design, conduct, analysis, synthesis and evaluation of key methodologies, the journal remains on the cusp of the latest topics, including ethics, regulation and policy impact.
期刊最新文献
Challenges in conducting efficacy trials for new COVID-19 vaccines in developed countries. Society for Clinical Trials Data Monitoring Committee initiative website: Closing the gap. A comparison of computational algorithms for the Bayesian analysis of clinical trials. Comparison of Bayesian and frequentist monitoring boundaries motivated by the Multiplatform Randomized Clinical Trial. Efficient designs for three-sequence stepped wedge trials with continuous recruitment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1